Results 281 to 290 of about 198,722 (342)

Case Report: Novel ASAP1::BRAF fusion in a young adult with low-grade temporal lobe glioma. [PDF]

Front Oncol
Gerasimou P, Vrachnos D, Kyprianou Y, Elpidoforou A, Miltiadous A, Mitsidou A, Nicolaou K, Shianiou G, Zartila C, Ioannou C, Christofi A, Georgiou E, Avgousti C, Kanezou M, Johnson M, Papanastassiou V, Oxinou C, Theodorou M, Shiarli AM, Antoniades A, Chi J, Costeas P.   +21 more
europepmc   +1 more source

Dysplasia in sessile serrated lesions: frequency, interobserver variability and added value of immunohistochemistry

Histopathology, EarlyView.
Sessile serrated lesions with dysplasia represent a critical step in colorectal carcinogenesis. While routine histologic diagnosis is generally reliable and positive diagnostic trends are observed, subtle dysplastic changes may be overlooked. Targeted use of MLH1 immunohistochemistry provides meaningful diagnostic support in selected sessile serrated ...
Valentina Angerilli, M. Elisa Vink‐Börger, Nanette S. van Roermund, Gesina van Lijnschoten, Chantal C.H.J. Kuijpers, Nicole C.T. van Grieken, Matteo Fassan, Joep E. Ijspeert, Rachel S. van der Post, Iris D. Nagtegaal   +9 more
wiley   +1 more source

Conversion Surgery after Chemotherapy in a Stage IV <i>BRAF</i> V600E-Mutated Laterally Spreading Tumor With Neuroendocrine Component. [PDF]

DEN Open
Kawamura R, Toyoshima N, Sekiguchi M, Takamaru H, Yamada M, Kobayashi N, Hirano H, Takamizawa Y, Hashimoto T, Saito Y.   +9 more
europepmc   +1 more source

The risk of radiation necrosis from combined radiotherapy and BRAF inhibitor in lung adenocarcinoma brain metastases: a comprehensive review and future perspectives. [PDF]

Front Oncol
Yang L, He Y, Peng Y, Sun M, Tang Z, Du L, Wu Y, Zhou W, Yang D.   +8 more
europepmc   +1 more source

Validating the 2022 WHO classification in thyroid carcinomas: Prospective evidence for predicting iodine resistance

Histopathology, EarlyView.
This study assessed the 2022 WHO classification for predicting RAIR disease in thyroid carcinomas, comparing it to older classifications. In a retrospective study of 253 cases, we found the 2022 classification more effective, especially by identifying high‐grade carcinomas and tumour necrosis as critical predictive factors.
Elise André, Laurine Mebarki, Mirela Ilie, Fabien Subtil, Claire Bournaud, Françoise Borson‐Chazot, Françoise Descotes, Jean‐Christophe Lifante, Mireille Bertholon‐Grégoire, Hélène Lasolle, Myriam Decaussin‐Petrucci   +10 more
wiley   +1 more source

A CLIP on the Ear: Spitz Melanocytoma Harbouring a CLIP2-BRAF Gene Fusion. [PDF]

Case Rep Dermatol Med
Moutasim KA, Atweh M, Theaker JM.
europepmc   +1 more source

Case Report: pembrolizumab monotherapy achieves durable disease control in a patient with <i>BRAF</i> V600E-mutant advanced lung adenocarcinoma and high PD-L1 expression intolerant to <i>BRAF</i>/<i>MEK</i> inhibition. [PDF]

Front Oncol
Zhao W, Zhou R, Feng C.
europepmc   +1 more source

Inhibition of fatty acid synthase enhances therapeutic efficacy and delays acquired resistance to BRAF-targeted therapy in colorectal cancer. [PDF]

Neoplasia
Geisen ME, Tessmann JW, Kelson CO, He D, Wang C, Faisal ASM, Beswick EJ, Baca Y, Rock S, Kolesar JM, Zaytseva YY.   +10 more
europepmc   +1 more source

Expert opinion on treatment patterns in metastatic colorectal cancer management in Eastern Europe. [PDF]

BMC Proc
Torday L, Hegmane A, Kukić B, Baltruškevičienė E, Sivina E, Luca I, Prejac J, Ristić M, Reberšek M, Milašević N, Ruseva RK, Jungić S, Minchev VT, Roblek T, Uršič V.   +14 more
europepmc   +1 more source

Concomitant <i>RAS</i> and <i>BRAF</i> V600E Mutations in Unresectable Metastatic CRC: A Case of Long-term Survival. [PDF]

J Anus Rectum Colon
Kitagawa K, Takahashi N, Fukuda M, Hannya Y, Kurita S, Shimoyama Y, Kumamoto T, Toya N, Eto K.   +8 more
europepmc   +1 more source